Skip to main content
. Author manuscript; available in PMC: 2017 Feb 15.
Published in final edited form as: Am J Cardiol. 2015 Dec 7;117(4):656–663. doi: 10.1016/j.amjcard.2015.11.029

Figure 3.

Figure 3

Aspirin effect in the chronic kidney disease (CKD) and the non-CKD groups as measured by the change in whole blood platelet aggregation (WBPA) induced by A) 0.5 mM arachidonic acid (AAA0.5) and B) 2 μg/mL collagen (CollA2) after 2 weeks of 81 mg of aspirin daily. Results are presented as mean and standard deviation. CKD is represented with closed circles and non-CKD with open triangles. There was a significant decrease in WBPA in both groups with CollA2 (p <0.0001) and with AAA0.5 (p <0.0001). The response at 2 weeks was not statistically different between CKD and non-CKD groups: group x time interaction p =0.29 for CollA2 and p =0.78 for AAA0.5.